Skip to content
type1.science

Medtronic MiniMed 780G (pump)

Medtronic

Medtronic's flagship tubed pump: a durable, rechargeable-battery-free body holding up to 300 units that runs the SmartGuard advanced hybrid closed-loop algorithm (ranked separately). It pairs with the Guardian 4 and Simplera Sync sensors and, since 2025, Abbott's Instinct sensor, supports a 7-day Extended infusion set, and is waterproof — but bolusing is done on the pump, not the phone. Available across the US, UK, EU and globally.

Available nowRegulator-approvedpumptubeddurable

The scorecard

Interoperability60

Works with Medtronic's Guardian 4 and Simplera Sync sensors and, since the 2025 iAGC clearance, Abbott's Instinct sensor — but it is a closed system that does not support DIY/open-source loops.[2]

Reliability80

Long Medtronic pump lineage with occlusion detection and a very large randomized and real-world evidence base; the Extended set's H-Cap connector is designed to cut occlusion risk over 7-day wear.[8]

Form factor55

A tubed, durable pump worn on a belt or pocket and waterproof to 12 ft for 24 h — robust and high-capacity, but less discreet than a tubeless patch.[4]

Phone control35

The MiniMed Mobile app is view-only for monitoring and sharing; all boluses are entered on the pump itself via the Bolus Wizard — no phone bolusing.[4]

Capacity80

Holds up to 300 units (3.0 mL) of U-100 insulin and pairs with a 7-day Extended infusion set — the longest reservoir-plus-set endurance in the class.[5]

Access & cost70

Broadly available worldwide and funded on the NHS under NICE's hybrid closed-loop rollout; as durable hardware it carries upfront pump cost plus ongoing reservoir/infusion-set and sensor consumables.[12]

Editor’s take

The high-capacity, do-everything tubed workhorse. Its 300-unit reservoir, 7-day infusion set and aggressive SmartGuard algorithm are genuine strengths, and the Abbott Instinct deal finally breaks Medtronic's sensor lock-in. The glaring gap versus Tandem and Omnipod is the lack of phone bolusing — in 2026 you still reach for the pump to eat.

The full picture

The MiniMed 780G is Medtronic's flagship insulin pump and the durable, high-capacity counterpoint to tubeless patch pumps: a robust pump body connected by thin tubing to an infusion set, running the SmartGuard advanced hybrid closed-loop algorithm.1 On this site the SmartGuard algorithm is ranked separately as an AID system; this record covers the pump hardware itself.

Form factor: a tubed, durable pump. Unlike a patch, the 780G is a reusable pump worn on a belt clip or in a pocket, with a length of tubing carrying insulin to a separately inserted infusion set.2 The pump body is waterproof — protected to a depth of 12 feet (3.6 m) for up to 24 hours (IPX8) when the reservoir and tubing are properly inserted — so it survives showers and swims, though many users disconnect for water.3

Reservoir and wear. The reservoir holds up to 300 units (3.0 mL) of U-100 rapid-acting insulin — meaningfully more than the ~200-unit ceiling of typical patch pumps, which suits people with higher insulin needs.24 The infusion set is changed separately from the reservoir, and if you run low on insulin you can swap the reservoir without re-siting the cannula.2

Infusion set, cannula and 7-day wear. The 780G works with Medtronic's range of infusion sets, and uniquely supports the Extended infusion set — the first and only set cleared to be worn for up to 7 days, versus the 2–3 days of conventional sets.45 Its new H-Cap tubing connector and materials are designed to improve insulin stability and reduce the risk of infusion-set occlusion over the longer wear, meaning fewer insertions.5

Occlusion detection and reliability. Like all Medtronic pumps it monitors delivery for blockages and alarms on a detected occlusion.2 It rests on one of the largest evidence bases of any pump: in the ADAPT randomized controlled trial, adults switched from injections to the 780G system lowered HbA1c by 1.54 percentage points (from 9.00% to 7.32%) versus near-no-change on injections, with no diabetic ketoacidosis or severe hypoglycemia related to the device, according to PubMed.6 Those gains were sustained at 12 months.7

Which CGMs and algorithms it works with. The pump runs SmartGuard with Medtronic's own Guardian 4 and Simplera Sync sensors, and — following a September 2025 FDA clearance of the SmartGuard algorithm as an interoperable automated glycemic controller (iAGC) — with Abbott's Instinct sensor, a 15-day wear CGM built for Medtronic AID.8 It is a closed commercial system and does not work with DIY/open-source loops.2

Phone bolusing. This is the pump's clearest limitation: the MiniMed Mobile app is view-only, for seeing glucose and pump data and sharing it with followers. Every bolus is still entered on the pump itself using the on-board Bolus Wizard — you cannot bolus from a phone, unlike Omnipod 5 or Tandem's phone-bolus systems.3

Access and cost by region. The 780G was FDA-approved in April 2023 for ages 7 and older with type 1 diabetes, and in 2025 gained a European CE Mark expanding use to children as young as 2, pregnancy, and insulin-requiring type 2 diabetes, plus US approval for type 2.198 It is sold across the US, UK, EU and globally; in England and Wales it is funded on the NHS under NICE's hybrid closed-loop program (TA943).10 As durable hardware it carries an upfront pump cost plus ongoing reservoir, infusion-set and sensor consumables.10

What's coming. Medtronic is rolling out the Abbott Instinct sensor and Simplera Sync disposable sensor to widen CGM choice and shrink on-body footprint, and has stated it plans to file for an interoperable pump indicated for type 2 diabetes to pair with Instinct in that population.8 Real-world data continue to push toward tighter targets — large analyses show users on the optimal settings (100 mg/dL target, 2-hour active insulin time) reaching ~57% time in tight range (70–140 mg/dL) and, in older adults, >80% time in range without added hypoglycemia, according to PubMed.1112

References

  1. Medtronic. FDA Approves Medtronic MiniMed 780G System — World's First Insulin Pump with Meal Detection Technology Featuring 5-Minute Auto Corrections (Apr 21, 2023; approved for ages 7+ with type 1 diabetes; SmartGuard auto-corrections every 5 minutes; glucose target as low as 100 mg/dL). https://news.medtronic.com/2023-04-21-FDA-Approves-Medtronic-MiniMed-TM-780G-System-Worlds-First-Insulin-Pump-with-Meal-Detection-Technology-Featuring-5-Minute-Auto-Corrections ↩ ↩2

  2. T1D Exchange. All About the Medtronic MiniMed 780G Closed-Loop Automated Insulin Pump System (tubed durable pump; up to 300-unit reservoir; reservoir swap without changing the infusion site; occlusion handling; SmartGuard up to 12 autocorrections/hour with meal detection; closed system). https://t1dexchange.org/medtronic-780g-hybrid-insulin-pump-features/ ↩ ↩2 ↩3 ↩4 ↩5

  3. Medtronic (MiniMed). MiniMed 780G System Support — FAQ (waterproof IPX8 to 12 ft / 3.6 m for up to 24 h; MiniMed Mobile app is view-only for monitoring/sharing; boluses entered on the pump via the Bolus Wizard). https://www.minimed.com/en-us/support/product-support/780g/faq/ ↩ ↩2

  4. Medtronic (MiniMed). Extended Infusion Set and Extended Reservoir — product overview (the only infusion set indicated for up to 7 days of wear; use the Extended set and reservoir with the MiniMed 780G system; up to 300 units). https://www.minimed.com/en-us/products/infusion-sets/extended-infusion-set/ ↩ ↩2

  5. Medtronic. Medtronic Secures FDA Clearance For First Ever Infusion Set That Can Be Worn Up To 7 Days By People With Diabetes (H-Cap connector improves insulin physical/chemical stability, increases infusion-site reliability, and reduces the risk of infusion-set occlusion; other sets are 2–3 days). https://news.medtronic.com/featured-stories?item=231 ↩ ↩2

  6. Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. The Lancet Diabetes & Endocrinology (2022); 10(10):720–731. According to PubMed. https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2822%2900212-1/fulltext (DOI) ↩

  7. Edd SN, Castañeda J, Choudhary P, et al. Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes. Diabetes, Obesity & Metabolism (2023); 25(11):3212–3222. According to PubMed. https://onlinelibrary.wiley.com/doi/10.1111/dom.15217 (DOI) ↩

  8. Medtronic. FDA Clears MiniMed 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes (Sep 2, 2025; SmartGuard cleared as an interoperable automated glycemic controller (iAGC); Abbott Instinct sensor up to 15-day wear; type 2 approval for adults 18+; Simplera Sync pre-orders; planned 510(k) for an interoperable type 2 pump). https://news.medtronic.com/2025-09-02-FDA-Clears-MiniMed-TM-780G-System-to-Enable-Integration-with-the-Instinct-Sensor,-Made-by-Abbott,-and-Approves-Use-in-Type-2-Diabetes ↩ ↩2 ↩3

  9. Medtronic. Medtronic secures CE Mark for MiniMed 780G System including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes (Jul 21, 2025; LENNY trial in children aged 2–6; pregnancy indication; European type 2 approval). https://news.medtronic.com/2025-07-21-Medtronic-secures-CE-Mark-for-MiniMed-TM-780G-System-for-insulin-requiring-people-with-diabetes-including-expanded-indications-in-children-as-young-as-two,-during-pregnancy,-and-for-type-2-diabetes ↩

  10. National Institute for Health and Care Excellence. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes — NICE technology appraisal guidance TA943 (recommends hybrid closed-loop systems, including the MiniMed 780G, on the NHS in England and Wales for eligible people with type 1 diabetes). https://www.nice.org.uk/guidance/ta943 ↩ ↩2

  11. Castañeda J, Arrieta A, van den Heuvel T, Battelino T, Cohen O. Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G System. Diabetes Care (2024); 47(5):790–797. According to PubMed. https://pmc.ncbi.nlm.nih.gov/articles/PMC11043222/ (DOI) ↩

  12. Smaniotto V, Heller S, O'Neal D, et al. MiniMed 780G system performance in older users with type 1 diabetes: Real-world evidence and the case for stricter glycaemic targets. Diabetes, Obesity & Metabolism (2025); 27(4):2242–2250. According to PubMed. https://pmc.ncbi.nlm.nih.gov/articles/PMC11885105/ (DOI) ↩

What's next for this

  • →Rollout of Abbott Instinct sensor and Simplera Sync disposable sensor to widen CGM choice
  • →Planned 510(k) filing for an interoperable pump indicated for type 2 diabetes to pair with Instinct

Sources

  1. [1]FDA Approves Medtronic MiniMed 780G System — World's First Insulin Pump with Meal Detection Technology Featuring 5-Minute Auto Corrections · manufacturer · 2023-04-21
  2. [2]FDA Clears MiniMed 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes · manufacturer · 2025-09-02
  3. [3]Medtronic secures CE Mark for MiniMed 780G System including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes · manufacturer · 2025-07-21
  4. [4]MiniMed 780G System Support — FAQ (waterproof rating, MiniMed Mobile app, Bolus Wizard) · manufacturer
  5. [5]Extended Infusion Set and Extended Reservoir — product overview (up to 7-day wear, use with MiniMed 780G) · manufacturer
  6. [6]Medtronic Secures FDA Clearance For First Ever Infusion Set That Can Be Worn Up To 7 Days By People With Diabetes (H-Cap connector, reduced occlusion risk) · manufacturer
  7. [7]All About the Medtronic MiniMed 780G Closed-Loop Automated Insulin Pump System · news
  8. [8]Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study · peer-reviewed · 2022-09-01
  9. [9]Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes · peer-reviewed · 2023-08-08
  10. [10]Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G System · peer-reviewed · 2024-05-01
  11. [11]MiniMed 780G system performance in older users with type 1 diabetes: Real-world evidence and the case for stricter glycaemic targets · peer-reviewed · 2025-02-04
  12. [12]Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes — NICE technology appraisal guidance TA943 · regulatory · 2023-12-19